This analysis demonstrated a statistically significant association between the TGFβ-EMT signature and presence of metastases in colon cancer patients (P = 0.0026), demonstrating that targeting this conserved pathway results in a signature that works in other cancer types. This evidence concerns the gene TGFB1 and colonic neoplasm.